Desonide

For the long-term management of chronic inflammatory skin diseases such as atopic dermatitis and contact dermatitis, the clinical demand for topical glucocorticoids with both efficacy and safety continues to rise. Desonide is a low-potency non-halogenated glucocorticoid. It binds to intracellular glucocorticoid receptors, inhibits the release of inflammatory mediators, and reduces the production of pro-inflammatory cytokines, thereby relieving inflammatory reactions such as skin redness, swelling, itching and exudation. With low transdermal absorption and low risk of systemic adverse reactions, it is one of the few topical hormone varieties that can be safely used in infants and children over 3 months old, and is also suitable for the treatment of inflammation in skin薄弱部位 such as the face and skin folds of adults.

In recent years, the global market size of desonide preparations has stabilized at around USD 320 million, among which the Chinese market has a significant growth rate, with a compound annual growth rate maintained at 8.7%. The main driving factors are the increase in the consultation rate of children with skin diseases and the popularization of the concept of standardized use of topical hormones. At present, generic drugs account for more than 75% of the domestic market, and topical creams and gels are the core dosage forms. As the centralized procurement policy for topical preparations extends to dermatological specialist drugs, the demand of relevant enterprises for compliant and high-quality desonide APIs and supporting impurity reference substances continues to rise.

The original developer of desonide is Mission Pharmacal, with the original brand name Desonate. The core U.S. compound patent expired in 2006, and all domestic compound patents have passed the protection period. The core dosage form of the original drug is a 0.05% concentration topical gel, which has been included in the FDA Reference Listed Drug Catalog. At present, 4 product specifications of desonide creams and gels have been approved for marketing in China. In terms of API registration, there are 3 domestic A-state registration numbers for desonide APIs, which can support the declaration and marketing of preparations. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of desonide impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide full-chain support for API enterprises and preparation manufacturers in impurity research, quality control and registration declaration.